[시장보고서]고분자 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 서비스별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

고분자 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 서비스별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Large Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Service, By Therapeutics Area, By End-use, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1771560

리서치사 : Grand View Research

발행일 : 2025년 06월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,675,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,133,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,049,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

고분자 Drug Discovery 아웃소싱 시장 요약

세계의 고분자 Drug Discovery 아웃소싱 시장 규모는 2024년에 28억 9,000만 달러에 달했고, 2025년부터 2030년에 걸쳐 CAGR 9.02%를 나타내 2030년에는 48억 3,000만 달러에 도달할 것으로 예측됩니다.

제약회사는 생물학적 제제에 대한 수요가 높아짐에 따라 저분자 화합물에서 펩티드, 재조합 단백질, 유전자 변형제 등의 대형 생체분자 화합물로의 변화를 강화하고 있습니다. 개발업무수탁기관(CRO)의 서비스를 적극적으로 요구하도록 되어 있습니다.

게다가 새로운 동향으로서 바이오제약기업과 CRO의 전략적 제휴가 주목받고 있으며, 혁신적인 플랫폼 기반 모델에 중점을 두어 연구개발 리스크를 경감하면서 자산의 진척을 높이는 역할을 하고 있습니다. 아웃소싱 서비스 수요는 과학적 전문지식의 깊이, 비용 대비 효과, 치료 영역의 전문성에 의해 영향을 받습니다.

게다가 북미와 아시아태평양 등 지역에 생물 제제 혁신의 거점을 요구하는 기업이 늘어나고 있으며, 시장의 세계적인 확대가 상황을 일변시키고 있습니다. 이러한 과학적 진보, 지리적 성장, 디지털 혁신의 조합에 의해 고분자 Drug Discovery 아웃소싱은 현대의 생물 제제 연구 개발 전략의 기본적인 측면으로서 확립하고 있습니다.

시장 계통 전망
- 상위 시장 전망
- 관련/보조시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
임상시험 건수 분석(2024년)
- 지역별 임상시험 총수
- 페이즈별 임상시험 총수
- 연구 디자인별 임상시험 총수
- 주요 치료 영역별 임상시험 총수
가격 모델 분석
기술 상황
시장 분석 도구
- Porter's Five Forces 분석
- SWOT 분석에 의한 PESTEL
- COVID-19의 영향 분석

제4장 고분자 Drug Discovery 아웃소싱 시장 : 워크플로우 추정·동향 분석

고분자 Drug Discovery 아웃소싱 시장(워크플로우별) : 부문 대시보드
고분자 Drug Discovery 아웃소싱 시장(워크플로우별) : 변동 분석
워크플로우별(2018-2030년)
대상 식별 및 심사
표적 검증 및 기능 정보학
리드 식별 및 후보 최적화
전임상 개발
기타

제5장 고분자 Drug Discovery 아웃소싱 시장 : 서비스 추정·동향 분석

고분자 Drug Discovery 아웃소싱 시장(서비스별) : 부문 대시보드
고분자 Drug Discovery 아웃소싱 시장(서비스별) : 변동 분석
서비스별(2018-2030년)
화학 서비스
생물학 서비스

제6장 고분자 Drug Discovery 아웃소싱 시장 : 치료제 영역 추정·동향 분석

고분자 Drug Discovery 아웃소싱 시장(치료제 영역별) : 부문 대시보드
고분자 Drug Discovery 아웃소싱 시장(치료제 영역별) : 변동 분석
치료 영역별(2018-2030년)
호흡기 시스템
통증 및 마취
종양학
안과
혈액학
심혈관
내분비
위장
면역 조절
항 감염성
중추 신경계
피부과
비뇨 생식기

제7장 고분자 Drug Discovery 아웃소싱 시장 : 최종 용도 추정·동향 분석

고분자 Drug Discovery 아웃소싱 시장(최종 용도별) : 부문 대시보드
고분자 Drug Discovery 아웃소싱 시장(최종 용도별) : 변동 분석
용도별(2018-2030년)
제약 및 바이오테크놀러지 기업
학술기관

제8장 고분자 Drug Discovery 아웃소싱 시장 : 지역 추정·동향 분석

지역 시장 대시보드
지역별 시장 점유율 분석(2024년 및 2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 태국
- 한국
- 호주
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

시장 진출기업의 분류
기업의 시장 점유율/평가 분석(2024년)
기업 프로파일
- Evotec SE
- Charles River Laboratories International, Inc.
- WuXi AppTec
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific Inc.
- Merck &Co. Inc.
- GenScript Biotech Corporation
- Jubilant Biosys Limited
- Pharmaron Beijing Co. Ltd.
- Syngene International Limited
- Dalton Pharma Services
- Domainex Ltd.
- Eurofins Scientific SE
- QIAGEN NV
- TCG Lifesciences Pvt Ltd.

KTH

영문 목차

영문목차

Large Molecule Drug Discovery Outsourcing Market Summary

The global large molecule drug discovery outsourcing market size was estimated at USD 2.89 billion in 2024 and is projected to reach USD 4.83 billion by 2030, growing at a CAGR of 9.02% from 2025 to 2030. The market is driven by increased demand for biologics and next-generation therapies.

Pharmaceutical companies are increasingly shifting their focus from small molecules to larger biomolecules, including peptides, recombinant proteins, and gene-modifying agents, due to rising demand for biologics. As a result, drug sponsors are actively seeking the services of contract research organizations (CROs) that specialize in drug discovery tailored to these biologics. This trend has led to a rise in outsourcing strategies that emphasize early-phase scientific collaboration and expertise in areas such as bioassay development, structural biology, and functional screening.

Furthermore, emerging trends highlight strategic partnerships between biopharma companies and CROs that focus on innovative platform-based models, which serve to mitigate R&D risks while enhancing the progression of assets. In addition, the demand for outsourcing services is more influenced by the depth of scientific expertise, cost effectiveness, and specialization in therapeutic areas. This has led increasing demand for collaboration with partners who have a strong focus on neurodegenerative diseases, rare disorders, and autoimmune conditions.

Moreover, the global expansion of the market is transforming the landscape, as companies seek biologics innovation hubs in regions like North America and Asia Pacific. In addition, CROs are integrating AI-driven tools, biomarker discovery platforms, and automated screening processes to enhance the accuracy of candidate selection. This combination of scientific advancement, geographical growth, and digital innovation is establishing large molecule discovery outsourcing as a fundamental aspect of modern biologics R&D strategies. Such factors are expected to drive market growth over the estimated time period.

Global Large Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global large molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, end-use, and region:

Workflow Outlook (Revenue, USD Million, 2018 - 2030)
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Others
Service Outlook (Revenue, USD Million, 2018 - 2030)
Chemistry Services
Biology Services
Therapeutics Area Outlook (Revenue, USD Million, 2018 - 2030)
Respiratory system
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
Cardiovascular
Endocrine
Gastrointestinal
Immunomodulation
Anti-infective
Central Nervous System
Dermatology
Genitourinary System
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology companies
Academic Institutes
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Asia Pacific
- Japan
- China
- India
- Thailand
- South Korea
- Australia
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- Argentina
- UAE
- Kuwait

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Workflow
- 1.2.2. Service
- 1.2.3. Therapeutics Area
- 1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Large Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Clinical Trials Volume Analysis, (2024)
- 3.3.1. Total Number Of Clinical Trials By Region
- 3.3.2. Total Number Of Clinical Trials, By Phase
- 3.3.3. Total Number Of Clinical Trials, By Study Design
- 3.3.4. Total Number Of Clinical Trials, By Key Therapeutic Area
3.4. Pricing Model Analysis
3.5. Technology Landscape
3.6. Market Analysis Tools
- 3.6.1. Porter's Five Force Analysis
- 3.6.2. PESTEL by SWOT Analysis
- 3.6.3. COVID-19 Impact Analysis

Chapter 4. Large Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

4.1. Large Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. Large Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2018 - 2030 (USD Million)
4.4. Target Identification & Screening
- 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Target Validation & Functional Informatics
- 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Lead Identification & Candidate Optimization
- 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Preclinical Development
- 4.7.1. Preclinical Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Large Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

5.1. Large Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
5.2. Large Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
5.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2018 - 2030 (USD Million)
5.4. Chemistry Services
- 5.4.1. Chemistry Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Biology Services
- 5.5.1. Biology Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Large Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

6.1. Large Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
6.2. Large Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
6.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2018 - 2030 (USD Million)
6.4. Respiratory system
- 6.4.1. Respiratory System Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Pain and Anesthesia
- 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Oncology
- 6.6.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Ophthalmology
- 6.7.1. Ophthalmology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Hematology
- 6.8.1. Hematology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Cardiovascular
- 6.9.1. Cardiovascular Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Endocrine
- 6.10.1. Endocrine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.11. Gastrointestinal
- 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.12. Immunomodulation
- 6.12.1. Immunomodulation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.13. Anti-infective
- 6.13.1. Anti-infective Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.14. Central Nervous System
- 6.14.1. Central Nervous System Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.15. Dermatology
- 6.15.1. Dermatology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.16. Genitourinary System
- 6.16.1. Genitourinary System Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Large Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

7.1. Large Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
7.2. Large Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
7.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
7.4. Pharmaceutical & Biotechnology companies
- 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Academic Institutes
- 7.5.1. Academic Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Large Molecule Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2024 & 2030
8.3. North America
- 8.3.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. U.S
  - 8.3.2.1. Key Country Dynamics
  - 8.3.2.2. Competitive Scenario
  - 8.3.2.3. Regulatory Framework
  - 8.3.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Canada
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Competitive Scenario
  - 8.3.3.3. Regulatory Framework
  - 8.3.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. Mexico
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Competitive Scenario
  - 8.3.4.3. Regulatory Framework
  - 8.3.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Europe
- 8.4.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. UK
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Competitive Scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Germany
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Competitive Scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. France
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Italy
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Competitive Scenario
  - 8.4.5.3. Regulatory Framework
  - 8.4.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. Spain
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Competitive Scenario
  - 8.4.6.3. Regulatory Framework
  - 8.4.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Denmark
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Competitive Scenario
  - 8.4.7.3. Regulatory Framework
  - 8.4.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.8. Sweden
  - 8.4.8.1. Key Country Dynamics
  - 8.4.8.2. Competitive Scenario
  - 8.4.8.3. Regulatory Framework
  - 8.4.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.9. Norway
  - 8.4.9.1. Key Country Dynamics
  - 8.4.9.2. Competitive Scenario
  - 8.4.9.3. Regulatory Framework
  - 8.4.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Asia Pacific
- 8.5.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Japan
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Competitive Scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. China
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. India
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Competitive Scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Thailand
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Competitive Scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. South Korea
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Australia
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Competitive Scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Latin America
- 8.6.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Brazil
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Competitive Scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Argentina
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Competitive Scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. MEA
- 8.7.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. South Africa
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Competitive Scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Saudi Arabia
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Competitive Scenario
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.4. UAE
  - 8.7.4.1. Key Country Dynamics
  - 8.7.4.2. Competitive Scenario
  - 8.7.4.3. Regulatory Framework
  - 8.7.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.5. Kuwait
  - 8.7.5.1. Key Country Dynamics
  - 8.7.5.2. Competitive Scenario
  - 8.7.5.3. Regulatory Framework
  - 8.7.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Market Participant Categorization
9.2. Company Market Share/Assessment Analysis, 2024
9.3. Company Profiles
- 9.3.1. Evotec SE
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Financial Performance
  - 9.3.1.3. Service Benchmarking
  - 9.3.1.4. Strategic Initiatives
- 9.3.2. Charles River Laboratories International, Inc.
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Financial Performance
  - 9.3.2.3. Service Benchmarking
  - 9.3.2.4. Strategic Initiatives
- 9.3.3. WuXi AppTec
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Financial Performance
  - 9.3.3.3. Service Benchmarking
  - 9.3.3.4. Strategic Initiatives
- 9.3.4. Laboratory Corporation of America Holdings
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Financial Performance
  - 9.3.4.3. Service Benchmarking
  - 9.3.4.4. Strategic Initiatives
- 9.3.5. Thermo Fisher Scientific Inc.
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Financial Performance
  - 9.3.5.3. Service Benchmarking
  - 9.3.5.4. Strategic Initiatives
- 9.3.6. Merck & Co., Inc.
  - 9.3.6.1. Company Overview
  - 9.3.6.2. Financial Performance
  - 9.3.6.3. Service Benchmarking
  - 9.3.6.4. Strategic Initiatives
- 9.3.7. GenScript Biotech Corporation
  - 9.3.7.1. Company Overview
  - 9.3.7.2. Financial Performance
  - 9.3.7.3. Service Benchmarking
  - 9.3.7.4. Strategic Initiatives
- 9.3.8. Jubilant Biosys Limited
  - 9.3.8.1. Company Overview
  - 9.3.8.2. Financial Performance
  - 9.3.8.3. Service Benchmarking
  - 9.3.8.4. Strategic Initiatives
- 9.3.9. Pharmaron Beijing Co., Ltd.
  - 9.3.9.1. Company Overview
  - 9.3.9.2. Financial Performance
  - 9.3.9.3. Service Benchmarking
  - 9.3.9.4. Strategic Initiatives
- 9.3.10. Syngene International Limited
  - 9.3.10.1. Company Overview
  - 9.3.10.2. Financial Performance
  - 9.3.10.3. Service Benchmarking
  - 9.3.10.4. Strategic Initiatives
- 9.3.11. Dalton Pharma Services
  - 9.3.11.1. Company Overview
  - 9.3.11.2. Financial Performance
  - 9.3.11.3. Service Benchmarking
  - 9.3.11.4. Strategic Initiatives
- 9.3.12. Domainex Ltd.
  - 9.3.12.1. Company Overview
  - 9.3.12.2. Financial Performance
  - 9.3.12.3. Service Benchmarking
  - 9.3.12.4. Strategic Initiatives
- 9.3.13. Eurofins Scientific SE
  - 9.3.13.1. Company Overview
  - 9.3.13.2. Financial Performance
  - 9.3.13.3. Service Benchmarking
  - 9.3.13.4. Strategic Initiatives
- 9.3.14. QIAGEN N.V.
  - 9.3.14.1. Company Overview
  - 9.3.14.2. Financial Performance
  - 9.3.14.3. Service Benchmarking
  - 9.3.14.4. Strategic Initiatives
- 9.3.15. TCG Lifesciences Pvt Ltd.
  - 9.3.15.1. Company Overview
  - 9.3.15.2. Financial Performance
  - 9.3.15.3. Service Benchmarking
  - 9.3.15.4. Strategic Initiatives